p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply

Affiliations

¹ Moores Cancer Center at University of California, San Diego, CA 92093, USA. Electronic address: ecohen@ucsd.edu.
² Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
³ Merck & Co, Kenilworth, NJ, USA.
⁴ The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, UK.

Comment

Ezra E W Cohen et al. Lancet. 2019.

. 2019 Oct 12;394(10206):1323.

doi: 10.1016/S0140-6736(19)31264-4.

¹ Moores Cancer Center at University of California, San Diego, CA 92093, USA. Electronic address: ecohen@ucsd.edu.
² Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
³ Merck & Co, Kenilworth, NJ, USA.
⁴ The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, UK.

No abstract available

Comment on

p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Wei W, Ji M, Wu CP, Yang X. Wei W, et al. Lancet. 2019 Oct 12;394(10206):1321-1322. doi: 10.1016/S0140-6736(19)31261-9. Lancet. 2019. PMID: 31609221 No abstract available.
p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Bins S, Mathijssen RHJ. Bins S, et al. Lancet. 2019 Oct 12;394(10206):1322-1323. doi: 10.1016/S0140-6736(19)31260-7. Lancet. 2019. PMID: 31609222 No abstract available.